Featured Research

University Of Southern California Researchers Find Cancer-Growing Role For Blood-Vessel Protein

Date:

September 20, 2001

Source:

University Of Southern California

Summary:

A key protein in the growth and survival of new blood vessels—a process called angiogenesis—can also directly promote the growth and survival of malignant tumor cells, according to research done by scientists at the Keck School of Medicine of the University of Southern California.

Share This

Los Angeles, CA. –– A key protein in the growth and survival of new blood vessels—a process called angiogenesis—can also directly promote the growth and survival of malignant tumor cells, according to research done by scientists at the Keck School of Medicine of the University of Southern California.

Related Articles

"We’ve shown that a protein that everybody knows is an angiogenesis regulator also regulates tumor cells directly," says Parkash Gill, M.D., professor of medicine and pathology at the Keck School and principal investigator on the paper, which was published in the September 15 issue of the journal Blood. "And this observation was not limited to one tumor type but rather to an extensive list of tumors. In other words, this principle has broad applications."

The protein in question, called vascular endothelial growth factor—or VEGF—has attracted a lot of attention for its role in the formation of new blood vessels. Cancer researchers have been particularly keen to find ways to inhibit VEGF’s effects in the body, since cutting off a tumor’s blood supply should stop it from growing and spreading.

But even the best of the new VEGF inhibitors have a hit and miss quality, notes Gill. "Some patients seem to respond," he explains, "while others don’t." In their study, Gill and his colleagues at the Keck School and the USC/Norris Comprehensive Cancer Center showed that the difference might lie in whether the patients’ tumor cells carry on their surface a receptor for the VEGF protein.

The researchers found production of VEGF and expression of a VEGF receptor on cell lines derived from Kaposi’s sarcomas, melanomas, ovarian carcinomas, pancreatic carcinomas and prostate carcinomas. "The coexpression of VEGF and its receptors in some of these tumor cell lines raised the possibility of autocrine growth factor activity," they write.

The best way to test this possibility, explains Gill, was to somehow stop VEGF from binding to the receptors, and see what happened to the tumors. To do this, the team used an inhibitor called VEGF AS-3 that they themselves had recently developed. "It’s a short stretch of DNA that blocks the production of the VEGF protein," explains Gill.

(The VEGF AS-3 inhibitor has been extensively tested in vitro and in animal models of ovarian cancer, prostate cancer, melanoma and Kaposi’s sarcoma, and is expected to begin clinical trials early next year. "One of the more exciting aspects," says Gill, "is that it utilizes chemistry that allows it to be given by mouth.")

When VEGF AS-3 was introduced to the cell lines, the normally proliferative cancer cells were brought to a near-standstill. The inhibitor had similar effects in mouse models of ovarian cancer, prostate cancer, pancreatic cancer and melanoma. In even more recent tests, it has been shown to also have an effect on malignant mesothelioma—a highly virulent, asbestos-related form of cancer.

The discovery that VEGF works directly on tumor cells that display its receptor may allow physicians to predict whether using a VEGF inhibitor as part of the therapy will produce a favorable outcome, says Gill. "We’re going to be able to test for the receptor on the tumor cells directly," he explains, "and thus predict response to VEGF inhibitors. We are now going to be able to sort out who is likely to respond most strongly to these drugs."

Of course, he adds, even those people who don’t carry the VEGF receptor will benefit from VEGF inhibitors, since those drugs will still be able to slow or halt angiogenesis. "When combined with other treatments," says Gill, "the VEGF inhibitors are especially useful because they have a different mechanism of action. We’ve found that they tend to add to each other’s activity—to be additive if not actually synergistic. This may be even more important in patients who are receptor negative, who will only have a blood vessel response to these inhibitors."

The work was supported in part by the National Institutes of Health, the Lynne Cohen Foundation and the University of California.

University Of Southern California. (2001, September 20). University Of Southern California Researchers Find Cancer-Growing Role For Blood-Vessel Protein. ScienceDaily. Retrieved March 3, 2015 from www.sciencedaily.com/releases/2001/09/010919073245.htm

More From ScienceDaily

More Health & Medicine News

Featured Research

Mar. 3, 2015 — Adults over the age of 30 only catch flu about twice a decade, a new study suggests. So, while it may feel like more, flu-like illness can be caused by many pathogens, making it difficult to assess ... full story

Mar. 3, 2015 — No significant change in home habits of smokers have been observed in the aftermath of a ban on smoking in public spaces, researchers report. Greater inspiration to kick the habit likely comes from ... full story

Mar. 3, 2015 — Heart function has been associated with the development of dementia and Alzheimer's disease through a new study. Participants with decreased heart function, measured by cardiac index, were two to ... full story

Mar. 3, 2015 — Children of recently separated or divorced families are likelier to drink sugar-sweetened beverages than children in families where the parents are married, putting them at higher risk for obesity ... full story

Mar. 3, 2015 — Gastric bypass and similar stomach-shrinking surgeries are a popular option for obese patients looking to lose weight or treat type 2 diabetes. While the surgeries have been linked to a decreased ... full story

Mar. 3, 2015 — Most people consume more salt than they need and therefore have a higher risk of heart disease and stroke, which are the two leading causes of death worldwide. But a new study reveals that dietary ... full story

Mar. 3, 2015 — Twice as many children born to mothers who took antibiotics during pregnancy were diagnosed with asthma by age 3 than children born to mothers who didn’t take prenatal antibiotics, a new study has ... full story

Mar. 3, 2015 — Although sedatives are often administered before surgery, a randomized trial finds that among patients undergoing elective surgery under general anesthesia, receiving the sedative lorazepam before ... full story

Mar. 3, 2015 — Pediatric otolaryngologists and surgeons are concerned with parents getting the wrong message regarding the safety/desirability of letting babies and young children eat peanuts to prevent them from ... full story

Featured Videos

Mom Triumphs Over Tragedy, Helps Other Families

AP (Mar. 3, 2015) — After her son, Dax, died from a rare form of leukemia, Julie Locke decided to give back to the doctors at St. Jude Children&apos;s Research Hospital who tried to save his life. She raised $1.6M to help other patients and their families. (March 3)
Video provided by AP

Looted and Leaking, South Sudan's Oil Wells Pose Health Risk

AFP (Mar. 3, 2015) — Thick black puddles and a looted, leaking ruin are all that remain of the Thar Jath oil treatment facility, once a crucial part of South Sudan&apos;s mainstay industry. Duration: 01:13
Video provided by AFP

Woman Convicted of Poisoning Son

AP (Mar. 3, 2015) — A woman who blogged for years about her son&apos;s constant health woes was convicted Monday of poisoning him to death by force-feeding heavy concentrations of sodium through his stomach tube. (March 3)
Video provided by AP

Related Stories

June 20, 2014 — Researchers are working towards cutting off the growth of pancreatic tumors before they can metastasize throughout the body. Pancreatic cancer and other cancers can only thrive, grow and spread if ... full story

Nov. 25, 2013 — A new mechanism that regulates the way blood vessels grow and connect to each other has been discovered by an international team of researchers. The knowledge might open up new opportunities for ... full story

Aug. 1, 2013 — New blood vessel formation (angiogenesis) stimulates the growth of cancer and other diseases. Anti-angiogenic inhibitors slow down cancer growth by disrupting the blood supply to the tumor. To date, ... full story

ScienceDaily features breaking news and videos about the latest discoveries in health, technology, the environment, and more -- from major news services and leading universities, scientific journals, and research organizations.